Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.52 USD | +5.88% |
|
+6.33% | +51.81% |
Jul. 01 | Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Value Index | CI |
Jul. 01 | Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Completeness Index | CI |
Business Summary
Number of employees: 14
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joel Lewis
CEO | Chief Executive Officer | 54 | 17-11-30 |
Jack Callicutt
DFI | Director of Finance/CFO | 56 | 13-06-30 |
Ezra R. lowe
CTO | Chief Tech/Sci/R&D Officer | - | - |
Pol Boudes
CTO | Chief Tech/Sci/R&D Officer | 67 | 20-03-01 |
Harold Shlevin
BRD | Director/Board Member | 75 | 12-09-30 |
Susan Thornton
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kevin Freeman
BRD | Director/Board Member | 62 | 11-04-30 |
Benjamin Carson
BRD | Director/Board Member | 73 | Dec. 06 |
Gil Omenn
BRD | Director/Board Member | 83 | 14-09-22 |
Gilbert Amelio
BRD | Director/Board Member | 81 | 09-02-11 |
Harold Shlevin
BRD | Director/Board Member | 75 | 12-09-30 |
Dick Uihlein
CHM | Chairman | 79 | 17-12-13 |
Marc Rubin
BRD | Director/Board Member | 69 | 11-10-11 |
Kary Eldred
BRD | Director/Board Member | 50 | 17-12-31 |
Richard Zordani
BRD | Director/Board Member | 52 | 20-08-31 |
Elissa Schwartz
BRD | Director/Board Member | 54 | 20-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,235,000 | 0 | 0 | 67.65 % |
Stock B | 1 | 62,148,134 | 42,878,905 ( 68.99 %) | 0 | |
Stock C | 0 | 176 | 0 | 0 |
Company contact information
Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard Suite 240
30071, Norcross
+(678) 620-3186
http://www.galectintherapeutics.com![address Galectin Therapeutics Inc.(GALT)](https://cdn.zonebourse.com/static/address/10274771.png)
Sector
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.37% | 148M | |
+22.15% | 46.56B | |
+45.32% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
-6.35% | 28.1B | |
+20.42% | 28.18B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
+0.06% | 12.17B |
- Stock Market
- Equities
- GALT Stock
- Company Galectin Therapeutics Inc.